The Lymphoma Research Foundation is holding another webinar this week that might be of interest to some of you. It's called "Update on Follicular Lymphoma," and it's happening this Thursday, June 27, from 3:00 to 4:00pm Eastern Time.
As the webinar's name suggests, this session will provide information on the latest research on topics related to Follicular Lymphoma. In particular, it will cover:
- Overview of Follicular Lymphoma (FL)
- Active Surveillance (Watch and Wait)
- Treatment Options for Newly Diagnosed Patients
- Treatment Options for Relapsed/Refractory Patients
- Emerging Treatment Options
So as you can see, no matter where you are with your FL, there is likely to be something useful for you.
I don't think they will be presenting anything brand new, the way they would at a medical conference. But it will probably provide the kind of 'big picture" that I always enjoy reading and watching -- here's the latest on Follicular Lymphoma. I think that kind of overview is really valuable, especially for newly diagnosed folks. Sometimes we're so focused on our own piece of the puzzle that we don't get a chance to step back and see the whole thing.
It's scheduled to last an hour, so I don't know how much depth they'll be able to go into, but it's still probably a great overview.
Speaking of "they" -- the presenters will be Dr. Philipe Armand, who is in charge of Lymphoma research at Dana-Farber in Boston, and Dr. Carla Casulo from the University of Rochester, where she is a professor ar their medical school. I don't know as much about Dr. Armand, but I have definitely heard Dr Casulo speak, and she's great. It should be an excellent webinar.
You can register online here. I hope you'll consider taking a look.
2 comments:
I watched this webinar... what I found interesting was when Dr. Casulo spoke about "relapse". I had been told that a relapse within two years of first treatment could mean shortened life expectancy. But Dr. Casulo changed this to ONE year and said those having a reoccurance within ONE year had a 30% survival rate. And as expected, each sucessive treatment provides a shorter remission. I had always been told that if the cancer returned within TWO years put you in a different category... so I found that interesting and hopeful.
The currently accepted standard is 2 years - that’s where “POD24” comes from: “Progression Of Disease within 24 months”. The suspicion amongst some lymphoma specialists is that this is a different type of FL that’s both more resistant to treatment and more aggressive / more likely to transform.
That said I wonder where Dr Casulo got their data from? I recall seeing some data sets that did seem to support the idea that the POD24 FL cohort did indeed seem to have quite different statistical outcomes than non-POD24 FL patients.
Post a Comment